PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Retatrutide

LY3437943; GGG tri-agonist

Classification: GIP/GLP-1/glucagon triple agonist

Mechanism: Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects

Benefits: Phase 2 weight loss ~24% at 48 weeks; strong lipid/metabolic effects; NAFLD reduction

Evidence tier: Phase 3 · Availability: Investigational

Primary sources

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med 2023. PMID 37366315

Loading interactive view…